ADX 10061

Drug Profile

ADX 10061

Alternative Names: ADX-10061; CEE 310; CEE-03-310; NNC 010687; NNC 687

Latest Information Update: 03 Oct 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Developer Addex Pharmaceuticals
  • Class Antipsychotics; Benzazepines; Sleep disorder therapies; Small molecules; Smoking cessation therapies
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Drug abuse; Schizophrenia; Sleep disorders; Smoking withdrawal

Most Recent Events

  • 03 Oct 2007 Discontinued - Phase-II for Smoking withdrawal in USA (PO)
  • 03 Aug 2007 Discontinued - Phase-II for Drug abuse in USA (PO)
  • 03 Aug 2007 Discontinued - Phase-II for Sleep disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top